DCBLD1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P02597(DCBLD1 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

DCBLD1 (Discoidin, CUB and LCCL domain-containing protein 1), also known as CLCP1 or ESDN, is a transmembrane glycoprotein belonging to the DCBLD family. Structurally, it contains extracellular discoidin, CUB, and LCCL domains, suggesting roles in protein-protein interactions and cellular signaling. DCBLD1 is implicated in cell adhesion, signal transduction, and angiogenesis, with homology to platelet-derived growth factor receptors. Studies highlight its potential involvement in cancer progression, as elevated DCBLD1 expression is observed in malignancies like lung cancer, glioblastoma, and colon cancer, where it may promote tumor growth, metastasis, or resistance to therapy.

Antibodies targeting DCBLD1 are essential tools for studying its expression, localization, and function. These antibodies, often monoclonal or polyclonal, are validated for applications such as Western blotting, immunohistochemistry (IHC), flow cytometry, and immunofluorescence. Specificity is confirmed using techniques like siRNA knockdown or overexpression models. DCBLD1 antibodies enable researchers to explore its tissue distribution, differential expression in diseases, and interaction partners. Notably, DCBLD1’s role in vascular remodeling and neurodevelopment has spurred interest in neurological and cardiovascular research.

Commercial DCBLD1 antibodies are typically raised against specific epitopes within its extracellular or intracellular regions, with cross-reactivity varying across species (human, mouse, rat). Their utility extends to both basic research and clinical diagnostics, particularly in cancer biomarker studies. However, validation in relevant experimental systems remains critical due to potential isoform diversity or post-translational modifications. Ongoing research aims to clarify DCBLD1’s mechanistic contributions to disease and its potential as a therapeutic target.